Tweet
Wall Street brokerages expect that Krystal Biotech Inc (NASDAQ:KRYS) will report earnings of ($0.31) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Krystal Biotech's earnings. Krystal Biotech reported earnings of ($1.26) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 75.4%. The company is expected to report its next quarterly earnings results on Monday, November 12th.
According to Zacks, analysts expect that Krystal Biotech will report full-year earnings of ($1.04) per share for the current year, with EPS estimates ranging from ($1.13) to ($0.92). For the next financial year, analysts anticipate that the company will post earnings of ($1.52) per share, with EPS estimates ranging from ($1.75) to ($1.26). Zacks Investment Research's earnings per share averages are an average based on a survey of analysts that that provide coverage for Krystal Biotech. Get Krystal Biotech alerts:
Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 6th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.12. Several analysts have commented on the stock. Zacks Investment Research raised shares of Krystal Biotech from a "hold" rating to a "buy" rating and set a $18.00 price objective on the stock in a research report on Saturday, August 11th. Chardan Capital reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Krystal Biotech in a research report on Monday, August 6th. William Blair started coverage on shares of Krystal Biotech in a research report on Monday, August 6th. They issued a "buy" rating on the stock. LADENBURG THALM/SH SH set a $38.00 price target on shares of Krystal Biotech and gave the company a "buy" rating in a research report on Thursday, July 19th. Finally, ValuEngine raised shares of Krystal Biotech from a "sell" rating to a "hold" rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of "Buy" and an average price target of $30.33.
Shares of KRYS stock opened at $15.43 on Tuesday. The stock has a market capitalization of $165.77 million and a price-to-earnings ratio of -10.74. Krystal Biotech has a 52 week low of $8.03 and a 52 week high of $19.25.
In other Krystal Biotech news, COO Suma Krishnan purchased 25,000 shares of the stock in a transaction dated Wednesday, June 6th. The shares were bought at an average price of $11.02 per share, with a total value of $275,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, CFO Antony A. Riley purchased 2,800 shares of the stock in a transaction dated Tuesday, May 22nd. The stock was acquired at an average cost of $10.75 per share, for a total transaction of $30,100.00. The disclosure for this purchase can be found here . Insiders own 45.80% of the company's stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its holdings in Krystal Biotech by 552.2% during the 2nd quarter. Acadian Asset Management LLC now owns 12,202 shares of the company's stock worth $182,000 after acquiring an additional 10,331 shares during the period. BlackRock Inc. increased its holdings in Krystal Biotech by 75.4% during the 2nd quarter. BlackRock Inc. now owns 13,040 shares of the company's stock worth $194,000 after acquiring an additional 5,607 shares during the period. Finally, Millennium Management LLC bought a new stake in Krystal Biotech during the 4th quarter worth approximately $266,000. 29.92% of the stock is currently owned by institutional investors.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Get a free copy of the Zacks research report on Krystal Biotech (KRYS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter 